<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690378</url>
  </required_header>
  <id_info>
    <org_study_id>NXL104/2001</org_study_id>
    <secondary_id>C3591013</secondary_id>
    <nct_id>NCT00690378</nct_id>
  </id_info>
  <brief_title>Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections</brief_title>
  <official_title>Prospective, Multicenter, Investigator-blinded, Randomized, Comparative Study Estimate Safety, Tolerability, Efficacy of NXL104/Ceftazidime vs. Comparator Followed Appropriate Oral Therapy Treatment Complicated UTI Hosp Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the
      treatment of complicated urinary tract infections as compared to a comparator group.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in CE Patients at the TOC Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit</measure>
    <time_frame>4 to 6 weeks post-therapy</time_frame>
    <description>Cure: all or most pre-therapy signs and symptoms of the index infection showed no evidence of resurgence and no additional antibiotic was required</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome in ME Patients at the End of IV Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome in ME Patients at the LFU Visit</measure>
    <time_frame>4 to 6 weeks post-therapy</time_frame>
    <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit</measure>
    <time_frame>End of IV therapy (4 to 14 days)</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit</measure>
    <time_frame>5 to 9 days post-therapy</time_frame>
    <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit</measure>
    <time_frame>4 to 6 weeks post-therapy</time_frame>
    <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit</measure>
    <time_frame>4 to 6 weeks post-therapy</time_frame>
    <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit</measure>
    <time_frame>4 to 6 weeks post-therapy</time_frame>
    <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit</measure>
    <time_frame>4 to 6 weeks post-therapy</time_frame>
    <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">137</enrollment>
  <condition>Complicated Urinary Tract Infection</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NXL/104 ceftazidime</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>comparator 4 x daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NXL104/ceftazidime</intervention_name>
    <description>125mg/500mg TID</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipenem/Cilastatin</intervention_name>
    <description>4 x daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute pyelonephritis or other complicated urinary tract infection due to gram negative
             pathogens

        Exclusion Criteria:

          -  ileal loops or vesicoureteral reflux

          -  complete obstruction of any portion of urinary tract, perinephric or intrarenal
             abscess.

          -  fungal urinary tract infection

          -  permanent indirect catheter or nephrostomy unless removed within 48 hours of study
             entry

          -  history hypersensitivity to study medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carole A Sable, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novexel Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Research Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Alabama Medical Center</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Hospital</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Pulmonary Specialists LTD</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Chula Vista Medical Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synergy Clinical Research Center</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novellus Research Sites</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novellus Research Sites</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Modesto Clinical Research</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri City Medical Center</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>EStudy Site</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olive View UCLA Medical Center</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Century Clinical Research, Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Regional Research Group</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's/Candler Health System</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Four Rivers Clinical Research Inc</name>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Louisiana State University Health Services Ctr Shreveport</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>R. Adams Cowley Shock Trauma Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Memorial Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis University Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James Healthcare</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newark Beth Israel Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital UMDNJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookdale University Hospital</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vassar Brothers Medical Center</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mission Hospital</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of America Inc.</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Summa Health System Hospitals</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Remington-Davis</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Infectious Disease-Infusion Center</name>
      <address>
        <city>Lima</city>
        <state>Ohio</state>
        <zip>45801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Mercy Medical Center</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson Univ Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Reading Hospital and Medical Center</name>
      <address>
        <city>West Reading</city>
        <state>Pennsylvania</state>
        <zip>19611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harris Methodist</name>
      <address>
        <city>Azle</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfold General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al-Essra hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Al-Islami Hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jordan University Hospital</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Abdullah University Hospital</name>
      <address>
        <city>Irbid</city>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique due Levant Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Rizk Clinic</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Makassed General Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rafik Hariri University Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahel General Hospital</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Notre Dame Des Secours Hospital</name>
      <address>
        <city>Byblos</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ain Wazein Hospital</name>
      <address>
        <city>Chouf</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Hospital</name>
      <address>
        <city>Dora</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Lebanon Hospital</name>
      <address>
        <city>Hazmieh</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nabatyeh Governmental Hospital</name>
      <address>
        <city>Nabatyeh</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammoud Hospital University Medical Center</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Labib Medical Center</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saida Governmental Hospital</name>
      <address>
        <city>Saida</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
    <country>Lebanon</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2008</study_first_submitted>
  <study_first_submitted_qc>June 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2008</study_first_posted>
  <results_first_submitted>September 1, 2017</results_first_submitted>
  <results_first_submitted_qc>April 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2018</results_first_posted>
  <last_update_submitted>April 27, 2018</last_update_submitted>
  <last_update_submitted_qc>April 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipenem</mesh_term>
    <mesh_term>Ceftazidime</mesh_term>
    <mesh_term>Avibactam</mesh_term>
    <mesh_term>Cilastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NXL104/CAZ</title>
          <description>NXL104 125mg/Ceftazidime 500mg TID</description>
        </group>
        <group group_id="P2">
          <title>Imipenem Cilastatin</title>
          <description>Imipenem cilastatin 500mg 4xdaily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69">Randomized</participants>
                <participants group_id="P2" count="68">Randomized</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49">Up to Late follow up (LFU) visit</participants>
                <participants group_id="P2" count="54">Up to LFU visit</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet inc/exc criteria</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Social problem</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population included all participants who received at least 1 dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>NXL104/CAZ</title>
          <description>NXL104 125mg/Ceftazidime 500mg TID</description>
        </group>
        <group group_id="B2">
          <title>Imipenem Cilastatin</title>
          <description>Imipenem cilastatin 500mg 4xdaily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="135"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.4" spread="18.24"/>
                    <measurement group_id="B2" value="49.9" spread="18.44"/>
                    <measurement group_id="B3" value="48.15" spread="18.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Microbiological Outcome at the Test of Cure (TOC) Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit</title>
        <description>Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in Clinically Evaluable (CE) Patients at the End of Intravenous (IV) Therapy Visit</title>
          <description>Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in CE Patients at the TOC Visit</title>
        <description>Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in CE Patients at the TOC Visit</title>
          <description>Cure: all or most pre-therapy signs and symptoms of the index infection had resolved and no additional antibiotic was required</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit</title>
        <description>Cure: all or most pre-therapy signs and symptoms of the index infection showed no evidence of resurgence and no additional antibiotic was required</description>
        <time_frame>4 to 6 weeks post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Outcome in CE Patients at the Late Follow-up (LFU) Visit</title>
          <description>Cure: all or most pre-therapy signs and symptoms of the index infection showed no evidence of resurgence and no additional antibiotic was required</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome in ME Patients at the End of IV Therapy Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome in ME Patients at the End of IV Therapy Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome in ME Patients at the LFU Visit</title>
        <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
        <time_frame>4 to 6 weeks post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome in ME Patients at the LFU Visit</title>
          <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the End of IV Therapy Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the End of IV Therapy Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the End of IV Therapy Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the End of IV Therapy Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>End of IV therapy (4 to 14 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the End of IV Therapy Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the TOC Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen E. Cloacae in ME Patients at the TOC Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the TOC Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the TOC Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit</title>
        <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
        <time_frame>5 to 9 days post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the TOC Visit</title>
          <description>Eradication: a uropathogen found at entry at &gt;10^5 CFU/mL was reduced to &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit</title>
        <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
        <time_frame>4 to 6 weeks post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen C. Koseri in ME Patients at the LFU Visit</title>
          <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit</title>
        <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
        <time_frame>4 to 6 weeks post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen E. Coli in ME Patients at the LFU Visit</title>
          <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit</title>
        <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
        <time_frame>4 to 6 weeks post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen P. Mirabilis in ME Patients at the LFU Visit</title>
          <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit</title>
        <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
        <time_frame>4 to 6 weeks post-therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NXL104/CAZ</title>
            <description>NXL104 125mg/Ceftazidime 500mg TID</description>
          </group>
          <group group_id="O2">
            <title>Imipenem Cilastatin</title>
            <description>Imipenem cilastatin 500mg 4xdaily</description>
          </group>
        </group_list>
        <measure>
          <title>Microbiological Outcome for the Urine Pathogen P. Aeruginosa in ME Patients at the LFU Visit</title>
          <description>Sustained eradication: a uropathogen found at entry at &gt;10^5 CFU/mL remained &lt;10^4 CFU/mL</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 19 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NXL104/CAZ</title>
          <description>NXL104 125mg/Ceftazidime 500mg TID</description>
        </group>
        <group group_id="E2">
          <title>Imipenem Cilastatin</title>
          <description>Imipenem cilastatin 500mg 4xdaily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Infusion Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Injection Site Reaction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="67"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="67"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If a Study Site, or an investigator, requests permission to publish data from this study, any such publication (including oral presentations) is to be agreed with AstraZeneca prior to publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

